Dr. Mark S. Adams

Internal Medicine
Marymount Medical Center Physician Services
1406 W 5th St Ste 201, 
London, KY 
Marymount Medical Center Physician Services
1406 W 5th St Ste 201, 
London, KY 

Overview

Mark Adams is a primary care provider, practicing in Internal Medicine in London, Kentucky.

His clinical expertise encompasses Migraine and Severe Acute Respiratory Syndrome (SARS).

He is actively involved in clinical research, participating in 21 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Marymount Medical Center Physician Services
1406 W 5th St Ste 201, London, KY 40741

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
Enrollment Status: Completed
Publish Date: April 10, 2023
Intervention Type: Biological, Other
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
38
conditions
Dr. Mateen M. Ahmed
Internal Medicine
Expertise in
38
conditions
Dr. Mateen M. Ahmed
Internal Medicine
Before you request

Pulmonary And Sleep Associates LLC

110 Hardin Ln Ste 10, 
Somerset, KY 
 (21.7 miles away)
606-678-0946
Languages Spoken:
English, Punjabi
See accepted insurances
Accepting New Patients

Mateen Ahmed is a primary care provider, practicing in Internal Medicine in Somerset, Kentucky. Dr. Ahmed is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma in Children, Asthma, and Advanced Bronchoscopy. Dr. Ahmed is currently accepting new patients.

Expertise in
30
conditions
Dr. Steven E. Morton
Internal Medicine
Expertise in
30
conditions
Dr. Steven E. Morton
Internal Medicine

Grace Community Health Center Inc.

14662 N US Highway 25 E, 
Corbin, KY 
 (11.9 miles away)
606-526-9005
Languages Spoken:
English
See accepted insurances

Steven Morton is a primary care provider, practicing in Internal Medicine in Corbin, Kentucky. Dr. Morton is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Familial Hypertension, Gastrostomy, and Endoscopy.

Expertise in
16
conditions
Dr. Christopher A. Troxell
Internal Medicine
Expertise in
16
conditions
Dr. Christopher A. Troxell
Internal Medicine

Office

2 Trillium Way Ste 306, 
Corbin, KY 
 (15.0 miles away)
606-526-4070
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Troxell is a primary care provider, practicing in Internal Medicine in Corbin, Kentucky. Dr. Troxell is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Atypical Pneumonia, Hospital-Acquired Pneumonia, Sepsis, Colonoscopy, and Endoscopy. Dr. Troxell is currently accepting new patients.

Frequently Asked Questions about Dr. Mark S. Adams

How do I make an appointment with Dr. Mark S. Adams?

You can book an appointment with Dr. Mark S. Adams by calling their office at 606-864-4137. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark S. Adams a top-rated expert for Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark S. Adams is classified as an Experienced expert for Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark S. Adams specialize in?

While Dr. Mark S. Adams is a Internal Medicine, they have specific expertise in Migraine, Severe Acute Respiratory Syndrome (SARS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Adams's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile